Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
OKURthis companyOnKure Therapeutics, Inc.	$2.84	-0.66×	0.7×	0×	0.33×	63.3%	0.0%	0.0%	0.0%	-105.9%	-110.9%	-132.3%	0.01×	1×	0×	10.28×	0.0%	2	6.84	3	B
ALGSAligos Therapeutics, Inc.	$4.55	-3.8×	1.72×	42.14×	-3.45×	-97.4%	57.5%	-4024.9%	-1106.7%	-45.2%	-123.9%	-90.0%	0.1×	0.57×	0×	3.9×	0.0%	2	-16.11	2	C
ATNMActinium Pharmaceuticals, Inc.	$1.58	-1.25×	5.42×	471.4×	0.12×	0.8%	100.0%	-40274.4%	-37652.2%	-432.6%	-81.4%	-58.2%	0.22×	1.4×	0×	6.2×	0.0%	4	-8.02	5	S-
CVMCEL-SCI Corporation	$1.48	-1.47×	2.34×	0×	-1.71×	-84.4%	0.0%	0.0%	0.0%	-159.2%	-97.4%	-46.0%	0.59×	0.08×	-38.23×	2.26×	0.0%	2	-38.36	2	C
PDSBPDS Biotechnology Corporation	$1.09	-1.04×	3.86×	0×	-0.86×	-89.5%	0.0%	0.0%	0.0%	-372.9%	-116.5%	-77.7%	1.83×	0.32×	-5.91×	2.98×	0.0%	2	-44.34	2	C
TPSTTempest Therapeutics, Inc.	$0.41	-0.45×	1.79×	0×	-0.48×	-172.7%	0.0%	0.0%	0.0%	-393.9%	-179.5%	-225.2%	1.22×	-0.02×	-128.38×	2.5×	0.0%	1	-53.69	2	C
Peer median	—	-1.25×	2.34×	0×	-0.86×	-89.5%	0.0%	0.0%	0.0%	-372.9%	-116.5%	-77.7%	0.59×	0.32×	-5.91×	2.98×	0.0%	2	-38.36	2	—